Loading...
Athira Pharma, Inc.
ATHA•NASDAQ
Healthcare
Biotechnology
$-0.44(-6.12%)
U.S. Market opens in 7h 36mAthira Pharma, Inc. (ATHA) AI-Powered Stock Analysis
See how Athira Pharma, Inc. scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerAthira Pharma, Inc. (ATHA) Stock Overall Grade
Athira Pharma, Inc.’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Athira Pharma, Inc.'s overall stock rating.
Forecast
C+Score
57/100Financial Growth
CScore
40/100Fundamental Growth
CScore
48/100Key Ratios
C+Score
55/100Sector Comparison
B+Score
75/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
97/100Analyst Consensus
C+Score
50/100Athira Pharma, Inc. (ATHA) AI-Powered Stock Analysis
This asset demonstrates Normal performance with an overall Forecast Score of 57/100 (C+), reflecting weak confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (48/100, C) highlight its stability, while Key Ratios (55/100, C+) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (97/100, A+), it shows competitive strength. Analyst Consensus (50/100,C+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each Athira Pharma, Inc. stock grade, including financials, comparisons, and forecasts.